Hodinový prehľad - Zdravotnícke a vedecké zaujímavosti

Súhrn: Adults with excessive daytime sleepiness (EDS) who also take 30 minutes or longer to fall asleep have more than triple the risk of developing hypertension compared to those without either symptom, new research suggests In a large observational cohort study, adults reporting EDS had 52% higher odds of prevalent hypertension and 74% higher odds of incident hypertension than their counterparts without EDS Although EDS alone was associated with increased hypertension risk, the combination of EDS and prolonged sleep-onset latency identified a “distinct subgroup” at substantially greater risk, study investigator Alexandros N.

Súhrn: The antibody-drug conjugate (ADC) mirvetuximab soravtansine boosts tumor response when added to standard chemotherapy for patients with platinum-sensitive ovarian cancer, but it does not improve their survival outcomes, according to a phase 2 trial Mirvetuximab is currently approved as monotherapy for patients with platinum-resistant ovarian cancer that’s folate receptor (FR) alpha-positive after they’ve received one to three prior systemic therapies In that setting, the ADC was shown to increase median overall survival by about 4 months compared with chemotherapy.

Súhrn: The FDA has approved palbociclib (Ibrance, Pfizer) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of hormone receptor-positive (HR+), HER2+ locally advanced or metastatic breast cancer following induction treatment In the phase 3 approval trial, PATINA, adding palbociclib to standard anti-HER2 and endocrine therapies for maintenance resulted in a 24% reduction in the risk for disease progression “Resistance to dual anti-HER2 and endocrine therapy remains a central clinical challenge for patients with HR+, HER2+ metastatic breast cancer — even after an excellent response to initial treatment,” said principal investigator Otto Metzger, MD, medical breast oncologist at the Dana-Farber Cancer Institute, in a Pfizer press release.

Súhrn: A large observational study reiterates the safety of taking acid-suppressive medications during pregnancy, finding no link to gastrointestinal disease in children The study, published in JAMA Network Open, found the relative risk for inflammatory bowel disease (IBD) was about 8% higher in kids whose mothers took prescription proton pump inhibitors (PPI) or H2 receptor antagonists (H2RAs) during pregnancy, while the risk for Crohn’s disease was 10% higher than in unexposed offspring However, when the researchers adjusted for confounding factors, they found no difference in risk for pediatric IBD, Crohn’s disease, or ulcerative colitis.